SCHEMBL3425870

SCHEMBL3425870

Cc1cc(Cl)nc(-c2ccccc2C)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.70
LMNA P02545 1/20 0.62
CYP1A2 P05177 4/20 0.44
CYP2C19 P33261 4/20 0.44
MEN1 O00255 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GPBAR1 Q8TDU6 2/20 0.43
HSP90AA1 P07900 1/20 0.42
TSHR P16473 3/20 0.41
CYP2D6 P10635 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATM Q13315 1/20 0.41
DPP4 P27487 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11286099 0.90 KMT2A (0.56) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL9375764 0.84 KMT2A (0.55) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL31296065 0.82 KMT2A (1.00) KMT2ALMNAMEN1NPC1TSHR
SCHEMBL24577342 0.81 KDM4E (0.53) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL12653948 0.78 KMT2A (0.60) KMT2ALMNAMEN1TSHRMAPK1
SCHEMBL786243 0.78 KMT2A (0.60) KMT2ALMNACYP1A2CYP2C19TSHR
SCHEMBL11810775 0.77 HSP90AA1 (0.55) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL1772953 0.77 LMNA (1.00) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL12697515 0.76 CYP1A2 (0.49) KMT2ALMNACYP1A2CYP2C19MEN1
SCHEMBL6172768 0.76 CYP1A2 (0.49) KMT2ALMNACYP1A2CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7731985-B2 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-06-08 US disclosed
EP-1484971-B1 USE OF 4-AMINOPYRIMIDINES FOR THE ANTIMICROBIAL TREATMENT OF SURFACES CIBA SC HOLDING AG (CH) 2007-07-04 EP disclosed
US-20050143387-A1 4-Aminopyrimidines and their use for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORP. 2005-06-30 US disclosed
EP-1484971-A1 4-AMINOPYRIMIDINES AND THEIR USE FOR THE ANTIMICROBIAL TREATMENT OF SURFACES Ciba SC Holding AG (CH) 2004-12-15 EP disclosed
WO-2003077656-A1 4-AMINOPYRIMIDINES AND THEIR USE FOR THE ANTIMICROBIAL TREATMENT OF SURFACES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143387-A1 4-Aminopyrimidines and their use for the antimicrobial treatment of surfaces DPM1, UNG, DPYD KMT2A 3109/4885LMNA 4211/4885CYP1A2 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.